- Home
- SKYE vs KOD Comparison
SKYE vs KOD Comparison
Compare SKYE & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- KOD
- Stock Information
- Founded
- SKYE 2012
- KOD 2009
- Country
- SKYE United States
- KOD United States
- Employees
- SKYE N/A
- KOD N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SKYE Health Care
- KOD Health Care
- Exchange
- SKYE Nasdaq
- KOD Nasdaq
- Market Cap
- SKYE 108.3M
- KOD 121.5M
- IPO Year
- SKYE N/A
- KOD 2018
- Fundamental
- Price
- SKYE $3.70
- KOD $2.64
- Analyst Decision
- SKYE Buy
- KOD Hold
- Analyst Count
- SKYE 6
- KOD 5
- Target Price
- SKYE $18.67
- KOD $3.25
- AVG Volume (30 Days)
- SKYE 615.6K
- KOD 158.7K
- Earning Date
- SKYE 11-09-2024
- KOD 11-12-2024
- Dividend Yield
- SKYE N/A
- KOD N/A
- EPS Growth
- SKYE N/A
- KOD N/A
- EPS
- SKYE N/A
- KOD N/A
- Revenue
- SKYE N/A
- KOD N/A
- Revenue This Year
- SKYE N/A
- KOD N/A
- Revenue Next Year
- SKYE N/A
- KOD N/A
- P/E Ratio
- SKYE N/A
- KOD N/A
- Revenue Growth
- SKYE N/A
- KOD N/A
- 52 Week Low
- SKYE $1.44
- KOD $1.37
- 52 Week High
- SKYE $19.41
- KOD $7.77
- Technical
- Relative Strength Index (RSI)
- SKYE 39.98
- KOD 53.50
- Support Level
- SKYE $3.46
- KOD $2.60
- Resistance Level
- SKYE $3.92
- KOD $2.75
- Average True Range (ATR)
- SKYE 0.50
- KOD 0.14
- MACD
- SKYE 0.01
- KOD 0.01
- Stochastic Oscillator
- SKYE 46.89
- KOD 72.34
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.